ID

26220

Beschrijving

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00688909

Link

https://clinicaltrials.gov/show/NCT00688909

Trefwoorden

Versies (1)
  1. 11-10-17 11-10-17 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

11 oktober 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Breast Cancer NCT00688909

Engels

Eligibility Breast Cancer NCT00688909

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. postmenopausal women with hr+ early stage breast cancer at the time of initial diagnosis. for study purposes, postmenopausal is defined as:
Beschrijving

Postmenopausal state | Early-Stage Breast Carcinoma Hormone Receptor Positive

Datatype

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2,1]
C2986665
UMLS CUI [2,2]
C0019929
UMLS CUI [2,3]
C1514241
age ≥ 50 y and amenorrheic for 12 or more months.
Beschrijving

Age | Amenorrhea Duration

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C0002453
UMLS CUI [2,2]
C0449238
age ≥ 50 y and amenorrheic for 3 or more months after receiving adjuvant chemotherapy.
Beschrijving

Age | Amenorrhea Duration | Status post Adjuvant Chemotherapy

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C0002453
UMLS CUI [2,2]
C0449238
UMLS CUI [3,1]
C0231290
UMLS CUI [3,2]
C0085533
age < 50 y and amenorrheic for 12 or more months.
Beschrijving

Age | Amenorrhea Duration

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C0002453
UMLS CUI [2,2]
C0449238
prior bilateral oophorectomy.
Beschrijving

Bilateral oophorectomy

Datatype

boolean

Alias
UMLS CUI [1]
C0278321
prior hysterectomy and has postmenopausal levels of fsh, lh, and estradiol as per local institutional standards.
Beschrijving

Hysterectomy | Follicle stimulating hormone measurement Postmenopausal state | Luteinizing hormone measurement Postmenopausal state | Estradiol measurement Postmenopausal state

Datatype

boolean

Alias
UMLS CUI [1]
C0020699
UMLS CUI [2,1]
C0202022
UMLS CUI [2,2]
C0232970
UMLS CUI [3,1]
C0202123
UMLS CUI [3,2]
C0232970
UMLS CUI [4,1]
C0337434
UMLS CUI [4,2]
C0232970
age > 55 y and prior hysterectomy.
Beschrijving

Age | Hysterectomy

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0020699
2. patients who are intolerant and discontinue anastrozole 2-3 weeks prior to study entry when given as adjuvant treatment for hr+ early stage breast cancer due to grade 2-3 (nci-ctcae v3) arthralgia-myalgia.
Beschrijving

Intolerance to Anastrozole | Anastrozole Discontinue | Adjuvant therapy Early-Stage Breast Carcinoma Hormone Receptor Positive | Arthralgia CTCAE Grades | Myalgia CTCAE Grades

Datatype

boolean

Alias
UMLS CUI [1,1]
C1744706
UMLS CUI [1,2]
C0290883
UMLS CUI [2,1]
C0290883
UMLS CUI [2,2]
C1444662
UMLS CUI [3,1]
C0677850
UMLS CUI [3,2]
C2986665
UMLS CUI [3,3]
C0019929
UMLS CUI [3,4]
C1514241
UMLS CUI [4,1]
C0003862
UMLS CUI [4,2]
C1516728
UMLS CUI [5,1]
C0231528
UMLS CUI [5,2]
C1516728
3. hormone receptor-positive tumors as defined by institutional standards.
Beschrijving

Hormone receptor positive tumor

Datatype

boolean

Alias
UMLS CUI [1]
C1563119
4. ecog performance status of 0, 1, or 2
Beschrijving

ECOG performance status

Datatype

boolean

Alias
UMLS CUI [1]
C1520224
5. consent to participate in the trial. -
Beschrijving

Informed Consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. postmenopausal women with hr+ metastatic or locally relapsed breast cancer excluding chest wall recurrence with no evidence of systemic disease.
Beschrijving

Postmenopausal state | Secondary malignant neoplasm of female breast Hormone Receptor Positive | Breast cancer recurrent Locally | Exception Chest wall Disease recurrence | Systemic disease Absent

Datatype

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2,1]
C0346993
UMLS CUI [2,2]
C0019929
UMLS CUI [2,3]
C1514241
UMLS CUI [3,1]
C0278493
UMLS CUI [3,2]
C1517927
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0205076
UMLS CUI [4,3]
C0679254
UMLS CUI [5,1]
C0442893
UMLS CUI [5,2]
C0332197
2. recent history of pain associated with non-traumatic bone fracture.
Beschrijving

Pain Associated with Bone Fracture

Datatype

boolean

Alias
UMLS CUI [1,1]
C0030193
UMLS CUI [1,2]
C0332281
UMLS CUI [1,3]
C0016658
3. pain requiring chronic use of analgesics (due to any reason).
Beschrijving

Pain Requirement Analgesics chronic

Datatype

boolean

Alias
UMLS CUI [1,1]
C0030193
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C0002771
UMLS CUI [1,4]
C0205191
4. history of rheumatological disease except osteoarthritis.
Beschrijving

Collagen Disease | Exception Osteoarthritis

Datatype

boolean

Alias
UMLS CUI [1]
C0009326
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0029408
5. prior hormonal therapy with ais other than anastrozole.
Beschrijving

Hormone Therapy | Aromatase Inhibitors | Exception Anastrozole

Datatype

boolean

Alias
UMLS CUI [1]
C0279025
UMLS CUI [2]
C0593802
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0290883
6. systemic hormone replacement therapy (hrt) less than 4 weeks before study entry other than estring®, vagifem® or low dose estrogen vaginal cream.
Beschrijving

Hormone replacement therapy Systemic | Exception Estring | Exception Vagifem | Exception Vaginal estrogens Low dose

Datatype

boolean

Alias
UMLS CUI [1,1]
C0282402
UMLS CUI [1,2]
C0205373
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0591465
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0592238
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1875126
UMLS CUI [4,3]
C0445550
7. concomitant disease which significantly affects quality of life.
Beschrijving

Comorbidity Affecting Quality of life

Datatype

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0034380
8. patient unable to complete self administered questionnaire.
Beschrijving

Questionnaire Self-Administered Completion Unable

Datatype

boolean

Alias
UMLS CUI [1,1]
C0034394
UMLS CUI [1,2]
C1519231
UMLS CUI [1,3]
C0205197
UMLS CUI [1,4]
C1299582
9. patients unable to sign consent form.
Beschrijving

Informed Consent Unable

Datatype

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C1299582
other protocol-defined inclusion/exclusion criteria may apply
Beschrijving

Clinical Trial Eligibility Criteria Study Protocol

Datatype

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C2348563
Terug naar het begin van de pagina

Similar models

Eligibility Breast Cancer NCT00688909

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state | Early-Stage Breast Carcinoma Hormone Receptor Positive
Item
1. postmenopausal women with hr+ early stage breast cancer at the time of initial diagnosis. for study purposes, postmenopausal is defined as:
boolean
C0232970 (UMLS CUI [1])
C2986665 (UMLS CUI [2,1])
C0019929 (UMLS CUI [2,2])
C1514241 (UMLS CUI [2,3])
Age | Amenorrhea Duration
Item
age ≥ 50 y and amenorrheic for 12 or more months.
boolean
C0001779 (UMLS CUI [1])
C0002453 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
Age | Amenorrhea Duration | Status post Adjuvant Chemotherapy
Item
age ≥ 50 y and amenorrheic for 3 or more months after receiving adjuvant chemotherapy.
boolean
C0001779 (UMLS CUI [1])
C0002453 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0231290 (UMLS CUI [3,1])
C0085533 (UMLS CUI [3,2])
Age | Amenorrhea Duration
Item
age < 50 y and amenorrheic for 12 or more months.
boolean
C0001779 (UMLS CUI [1])
C0002453 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
Bilateral oophorectomy
Item
prior bilateral oophorectomy.
boolean
C0278321 (UMLS CUI [1])
Hysterectomy | Follicle stimulating hormone measurement Postmenopausal state | Luteinizing hormone measurement Postmenopausal state | Estradiol measurement Postmenopausal state
Item
prior hysterectomy and has postmenopausal levels of fsh, lh, and estradiol as per local institutional standards.
boolean
C0020699 (UMLS CUI [1])
C0202022 (UMLS CUI [2,1])
C0232970 (UMLS CUI [2,2])
C0202123 (UMLS CUI [3,1])
C0232970 (UMLS CUI [3,2])
C0337434 (UMLS CUI [4,1])
C0232970 (UMLS CUI [4,2])
Age | Hysterectomy
Item
age > 55 y and prior hysterectomy.
boolean
C0001779 (UMLS CUI [1])
C0020699 (UMLS CUI [2])
Intolerance to Anastrozole | Anastrozole Discontinue | Adjuvant therapy Early-Stage Breast Carcinoma Hormone Receptor Positive | Arthralgia CTCAE Grades | Myalgia CTCAE Grades
Item
2. patients who are intolerant and discontinue anastrozole 2-3 weeks prior to study entry when given as adjuvant treatment for hr+ early stage breast cancer due to grade 2-3 (nci-ctcae v3) arthralgia-myalgia.
boolean
C1744706 (UMLS CUI [1,1])
C0290883 (UMLS CUI [1,2])
C0290883 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C0677850 (UMLS CUI [3,1])
C2986665 (UMLS CUI [3,2])
C0019929 (UMLS CUI [3,3])
C1514241 (UMLS CUI [3,4])
C0003862 (UMLS CUI [4,1])
C1516728 (UMLS CUI [4,2])
C0231528 (UMLS CUI [5,1])
C1516728 (UMLS CUI [5,2])
Hormone receptor positive tumor
Item
3. hormone receptor-positive tumors as defined by institutional standards.
boolean
C1563119 (UMLS CUI [1])
ECOG performance status
Item
4. ecog performance status of 0, 1, or 2
boolean
C1520224 (UMLS CUI [1])
Informed Consent
Item
5. consent to participate in the trial. -
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Postmenopausal state | Secondary malignant neoplasm of female breast Hormone Receptor Positive | Breast cancer recurrent Locally | Exception Chest wall Disease recurrence | Systemic disease Absent
Item
1. postmenopausal women with hr+ metastatic or locally relapsed breast cancer excluding chest wall recurrence with no evidence of systemic disease.
boolean
C0232970 (UMLS CUI [1])
C0346993 (UMLS CUI [2,1])
C0019929 (UMLS CUI [2,2])
C1514241 (UMLS CUI [2,3])
C0278493 (UMLS CUI [3,1])
C1517927 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0205076 (UMLS CUI [4,2])
C0679254 (UMLS CUI [4,3])
C0442893 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
Pain Associated with Bone Fracture
Item
2. recent history of pain associated with non-traumatic bone fracture.
boolean
C0030193 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0016658 (UMLS CUI [1,3])
Pain Requirement Analgesics chronic
Item
3. pain requiring chronic use of analgesics (due to any reason).
boolean
C0030193 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0002771 (UMLS CUI [1,3])
C0205191 (UMLS CUI [1,4])
Collagen Disease | Exception Osteoarthritis
Item
4. history of rheumatological disease except osteoarthritis.
boolean
C0009326 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0029408 (UMLS CUI [2,2])
Hormone Therapy | Aromatase Inhibitors | Exception Anastrozole
Item
5. prior hormonal therapy with ais other than anastrozole.
boolean
C0279025 (UMLS CUI [1])
C0593802 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0290883 (UMLS CUI [3,2])
Hormone replacement therapy Systemic | Exception Estring | Exception Vagifem | Exception Vaginal estrogens Low dose
Item
6. systemic hormone replacement therapy (hrt) less than 4 weeks before study entry other than estring®, vagifem® or low dose estrogen vaginal cream.
boolean
C0282402 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0591465 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0592238 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1875126 (UMLS CUI [4,2])
C0445550 (UMLS CUI [4,3])
Comorbidity Affecting Quality of life
Item
7. concomitant disease which significantly affects quality of life.
boolean
C0009488 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0034380 (UMLS CUI [1,3])
Questionnaire Self-Administered Completion Unable
Item
8. patient unable to complete self administered questionnaire.
boolean
C0034394 (UMLS CUI [1,1])
C1519231 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C1299582 (UMLS CUI [1,4])
Informed Consent Unable
Item
9. patients unable to sign consent form.
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Clinical Trial Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial